Genvoya (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) 150/150/200/10mg

Elvitegravir+Cobicistat+Emtricitabine+Tenofovir Alafenamide, Genvoya
Description: Antiretroviral, Integrase Inhibitor (Anti-HIV); Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV); Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV); Cytochrome P-450 Inhibitor

“ALERT: US Boxed Warning

Post-treatment acute exacerbation of hepatitis B:
Severe, acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue this fixed-dose combination. If appropriate, antihepatitis B therapy may be warranted.”

CSA NA – FDA Approved – REMS (N) – Can Ship

A combination of an integrase strand transfer inhibitor, CYP3A enzyme inhibitor plus nucleoside and nucleotide reverse transcriptase inhibitor.  The viral cDNA strand produced by reverse transcriptase is processed and inserted into the human genome by the enzyme HIV-1 integrase.
Elvitegravir inhibits the catalytic activity of integrase, thereby preventing integration of the proviral gene into human DNA.
Cobicistat inhibits the CYP3A subfamily and enhances systemic exposure to elvitegravir.
Tenofovir alafenamide is converted to tenofovir in the body. Tenofovir is an analog of adenosine 5′-monophosphate. Emtricitabine (a cytosine analogue) and tenofovir interfere with HIV viral RNA dependent DNA polymerase activities resulting in inhibition of viral replication.

HIV-1 Infection

Before starting Elvitegravir+Cobicistat+Emtricitabine+Tenofovir Alafenamide, Genvoya make sure your physician is aware of any allergies or medications you currently take, if you chronic hepatitis B, hepatic impairment, renal impairment, are pregnant or breastfeeding. Elvitegravir+Cobicistat+Emtricitabine+Tenofovir Alafenamide, Genvoya use has been associated with rare but potentially serious adverse events such as immune reconstitution syndrome, lactic acidosis, severe hepatomegaly, and renal toxicity.

Oral: One tablet once daily (elvitegravir 150 mg+cobicistat 150 mg+emtricitabine 200 mg+tenofovir alafenamide 10 mg)

How to Take: Follow instructions provided by physician/pharmacy label, take consistently at same times each day with food unless otherwise directed, store at room temperature.

You Need to Avoid:  Do not start any natural health products, supplements, or new medications without informing your prescriber as this medication has many interactions with other products.

Increased LDL cholesterol, nausea, decreased bone mineral density, increased serum creatine kinase, headache, fatigue, increased serum cholesterol, diarrhea 

Note this is not a complete list of side effects, only the most common

1. Do I have to take this medication every day?
   Do not stop taking this medication, it is very important because the amount of virus in your blood may increase if the medicine is stopped even for a short time. The virus may develop resistance to this medication and become harder to treat.
2. What do I do if side effects are intolerable?
   If side effects are causing a lot of distress speak to your physician as soon as possible to discuss options.